The aim of the present study was to evaluate the relationship of serum adiponectin and RBP4 not only with PAD, but with MACE during 6-month follow-up of patients with symptomatic PAD undergoing lower limb endovascular revascularization. The gene discussed is RBP4; the disease is peripheral arterial disease.